Kymera Therapeutics, Inc. (KYMR)Healthcare | Biotechnology | Watertown, United States | NasdaqGM
118.15 USD
-2.08
(-1.730%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 118.15 |
Hot Take ↕ | Aug. 22, 2026, 2:47 a.m. EDT
Kymera is riding a wave of clinical optimism and technical strength, but the financials remain speculative. The stock has rallied significantly over the last two months, trading well above its 50-day and 200-day moving averages, which supports a bullish short-term view. However, the company is still burning cash with negative earnings and a high valuation relative to sales. While the balance sheet is healthy enough to weather the storm, the lack of profitability prevents a top-tier long-term rating. Options traders are pricing in significant volatility, with heavy call interest at higher strikes suggesting a belief in further upside, though put volume indicates a fear of a pullback. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.211193 |
| AutoETS | 0.211193 |
| AutoTheta | 0.211254 |
| MSTL | 0.221487 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 1.27 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.748 |
| Excess Kurtosis | -0.36 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 5.205 |
| Revenue per Share | 1.126 |
| Market Cap | 9,824,245,760 |
| Forward P/E | -24.05 |
| Beta | 1.95 |
| Profit Margins | -285.33% |
| Website | https://www.kymeratx.com |
As of Aug. 22, 2026, 2:47 a.m. EDT: Implied volatility remains elevated, signaling uncertainty. Call buyers are positioning for upside beyond $140, while put writers and buyers are hedging downside risks in the $70-$100 range. The skew suggests a risk-on bias tempered by volatility protection.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.9547801 |
| Address1 | 500 North Beacon Street |
| Address2 | 4th Floor |
| All Time High | 130.05 |
| All Time Low | 9.6 |
| Ask | 133.99 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 628,670 |
| Average Daily Volume3 Month | 863,000 |
| Average Volume | 863,000 |
| Average Volume10Days | 628,670 |
| Beta | 1.954 |
| Bid | 75.27 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 18.23 |
| City | Watertown |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 118.15 |
| Current Ratio | 10.337 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 121.975 |
| Day Low | 117.51 |
| Debt To Equity | 5.205 |
| Display Name | Kymera Therapeutics |
| Earnings Call Timestamp End | 1,785,933,000 |
| Earnings Call Timestamp Start | 1,785,933,000 |
| Earnings Timestamp | 1,785,933,000 |
| Earnings Timestamp End | 1,793,709,000 |
| Earnings Timestamp Start | 1,793,709,000 |
| Ebitda | -339,891,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -27.611 |
| Enterprise To Revenue | 89.379 |
| Enterprise Value | 9,384,771,584 |
| Eps Current Year | -3.79816 |
| Eps Forward | -4.9136 |
| Eps Trailing Twelve Months | -3.25 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 111.7532 |
| Fifty Day Average Change | 6.396805 |
| Fifty Day Average Change Percent | 0.057240464 |
| Fifty Two Week Change Percent | 195.47801 |
| Fifty Two Week High | 130.05 |
| Fifty Two Week High Change | -11.900002 |
| Fifty Two Week High Change Percent | -0.09150328 |
| Fifty Two Week Low | 39.84 |
| Fifty Two Week Low Change | 78.31 |
| Fifty Two Week Low Change Percent | 1.9656124 |
| Fifty Two Week Range | 39.84 - 130.05 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,598,016,600,000 |
| Float Shares | 66,061,503 |
| Forward Eps | -4.9136 |
| Forward P E | -24.045507 |
| Free Cashflow | -144,066,752 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 273 |
| Fullday Change | -2.08 |
| Fullday Change Percent | -1.73002 |
| Fullday Price | 118.15 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | -2.57685 |
| Gross Profits | -270,568,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02121 |
| Held Percent Institutions | 1.17097 |
| Implied Shares Outstanding | 83,150,618 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-08-21 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts. |
| Long Name | Kymera Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 9,824,245,760 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_542085131 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -299,600,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 9,976,411,147 |
| Number Of Analyst Opinions | 22 |
| Open | 119.4 |
| Operating Cashflow | -236,762,000 |
| Operating Margins | -1.16318 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 857 285 5300 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 118.15 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 120.23 |
| Price Eps Current Year | -31.107168 |
| Price Hint | 2 |
| Price To Book | 6.4810753 |
| Price To Sales Trailing12 Months | 93.56425 |
| Profit Margins | -2.8533401 |
| Quick Ratio | 9.968 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.41667 |
| Region | US |
| Regular Market Change | -2.08 |
| Regular Market Change Percent | -1.73002 |
| Regular Market Day High | 121.975 |
| Regular Market Day Low | 117.49 |
| Regular Market Day Range | 117.49 - 121.975 |
| Regular Market Open | 119.4 |
| Regular Market Previous Close | 120.23 |
| Regular Market Price | 118.15 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 415,930 |
| Return On Assets | -0.15592 |
| Return On Equity | -0.24154 |
| Revenue Growth | 4.664 |
| Revenue Per Share | 1.126 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 83,150,618 |
| Shares Percent Shares Out | 0.1249 |
| Shares Short | 10,382,744 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 9,900,469 |
| Short Name | Kymera Therapeutics, Inc. |
| Short Percent Of Float | 0.16059999 |
| Short Ratio | 16.51 |
| Source Interval | 15 |
| State | MA |
| Symbol | KYMR |
| Target High Price | 155.0 |
| Target Low Price | 111.0 |
| Target Mean Price | 130.90909 |
| Target Median Price | 133.0 |
| Total Cash | 690,985,024 |
| Total Cash Per Share | 8.31 |
| Total Debt | 78,558,000 |
| Total Revenue | 105,000,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.25 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 87.44695 |
| Two Hundred Day Average Change | 30.703049 |
| Two Hundred Day Average Change Percent | 0.35110486 |
| Type Disp | Equity |
| Volume | 415,930 |
| Website | https://www.kymeratx.com |
| Zip | 2,472 |